title: Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
abstract: A majority of nanoencapsulated drugs that have shown promise in cancer chemotherapy are administered intravenously. Development of effective oral nanoformulations presents a very challenging medical goal. Here, we describe successful applications of innovative polymeric nanogels in the form of conjugates with activated nucleoside analogs for oral administration in cancer chemotherapy. Previously, we reported the synthesis of amphiphilic polyvinyl alcohol and dextrin-based nanogel conjugates with the phosphorylated 5-FU nucleoside Floxuridine and demonstrated their enhanced activity against regular and drug-resistant cancers (T.H. Senanayake, G. Warren, S.V. Vinogradov, Novel anticancer polymeric conjugates of activated nucleoside analogs, Bioconjug. Chem. 22 (2011) 1983-1993). In this study, we synthesized and evaluated oral applications of nanogel conjugates of a protected Gemcitabine, the drug never used in oral therapies. These conjugates were able to quickly release an active form of the drug (Gemcitabine 5'-mono-, di- and triphosphates) by specific enzymatic activities, or slowly during hydrolysis. Gemcitabine conjugates demonstrated up to 127 times higher in vitro efficacy than the free drug against various cancer cells, including the lines resistant to nucleoside analogs. Surprisingly, these nanogel-drug conjugates were relatively stable in gastric conditions and able to actively penetrate through the gastrointestinal barrier based on permeability studies in Caco-2 cell model. In tumor xenograft models of several drug-resistant human cancers, we observed an efficient inhibition of tumor growth and extended the life-span of the animals by 3 times that of the control with orally treated Gemcitabine- or Floxuridine-nanogel conjugates. Thus, we have demonstrated a potential of therapeutic nanogel conjugates with the activated and stabilized Gemcitabine as a successful oral drug form against Gemcitabine-resistant and other drug-resistant tumors.
authors: Department of Pharmaceutical Sciences and Center for Drug Delivery and Nanomedicine, College of Pharmacy, University of Nebraska Medical Center, Omaha, United States.
authors: Thulani H
authors: TH
authors: Senanayake
authors: Galya
authors: G
authors: Warren
authors: Xin
authors: X
authors: Wei
authors: Serguei V
authors: SV
authors: Vinogradov
mesh_terms: D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000737:chemistry; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D002784:Cholesterol / Q000737:chemistry; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D006868:Hydrolysis; D051379:Mice; D008819:Mice, Nude; D049329:Nanostructures / Q000008:administration & dosage* / Q000737:chemistry; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010316:Particle Size; D010539:Permeability; D010727:Phosphoric Diester Hydrolases / Q000737:chemistry; D047368:Tumor Burden / Q000187:drug effects; D023041:Xenograft Model Antitumor Assays; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D002784:Cholesterol; D000469:Alkaline Phosphatase; D010727:Phosphoric Diester Hydrolases; D000093542:Gemcitabine
references: Pharm Res. 1998 Aug;15(8):1160-7
references: 9706044
references: J Pharm Sci. 1990 Jun;79(6):476-82
references: 1975619
references: Int J Pharm. 2010 Aug 16;395(1-2):281-9
references: 20580798
references: Arch Dis Child. 1994 Nov;71(5):457-62
references: 7826122
references: Bioconjug Chem. 2010 May 19;21(5):797-802
references: 20397686
references: Clin Cancer Res. 2004 Oct 15;10(20):6956-61
references: 15501974
references: Ann Intern Med. 1979 Nov;91(5):710-7
references: 496103
references: N Engl J Med. 1991 Mar 21;324(12):808-15
references: 1997853
references: Nano Lett. 2006 Apr;6(4):662-8
references: 16608261
references: Nucleic Acids Res. 1989 Jun 26;17(12):4863-71
references: 2748339
references: J Am Coll Cardiol. 2007 Oct 9;50(15):1435-41
references: 17919562
references: Pharmacol Rev. 2006 Sep;58(3):488-520
references: 16968949
references: J Control Release. 2005 Sep 20;107(1):143-57
references: 16039001
references: J Control Release. 2002 Apr 23;80(1-3):129-44
references: 11943393
references: Pharm Res. 2005 Sep;22(9):1510-8
references: 16132363
references: Gastroenterology. 1989 Mar;96(3):736-49
references: 2914637
references: Leuk Lymphoma. 1998 Dec;32(1-2):45-54
references: 10037000
references: J Pharm Pharmacol. 1995 Jun;47(6):479-86
references: 7674130
references: Pharm Acta Helv. 1983;58(8):217-26
references: 6622500
references: World J Gastrointest Oncol. 2010 Aug 15;2(8):311-21
references: 21160892
references: Biochem Pharmacol. 2003 Jan 1;65(1):121-9
references: 12473386
references: Nat Nanotechnol. 2008 Mar;3(3):145-50
references: 18654486
references: Eur J Biochem. 1991 Mar 14;196(2):451-7
references: 1848820
references: Lancet Oncol. 2002 Jul;3(7):415-24
references: 12142171
references: J Pharm Sci. 2000 Jul;89(7):850-66
references: 10861586
references: J Biomed Opt. 2010 Jan-Feb;15(1):015003
references: 20210443
references: Pharm Res. 1997 Dec;14(12):1835-7
references: 9453077
references: Leuk Lymphoma. 1998 Oct;31(3-4):405-9
references: 9869205
references: Cancer Metastasis Rev. 2007 Mar;26(1):85-110
references: 17345146
references: Clin Cancer Res. 2008 Jun 1;14(11):3477-86
references: 18519780
references: Drug Metab Pharmacokinet. 2007 Apr;22(2):67-77
references: 17495413
references: Infection. 1991;19 Suppl 4:S224-8
references: 1879957
references: Biomaterials. 2005 May;26(15):2713-22
references: 15585275
references: Ann Oncol. 2005 Oct;16(10):1624-31
references: 16030028
references: Bioconjug Chem. 2011 Oct 19;22(10):1983-93
references: 21863885
references: J Pharm Sci. 2005 Jun;94(6):1343-53
references: 15858853
references: Clin Ther. 2009 Aug;31(8):1619-40
references: 19808124